Lange et al. predicted that conventional therapy (radiotherapy and temozolomide) combined with CHI3L1 targeted inhibitors, mainly grade IV chemotherapy, may provide better outcomes for patients with a poor prognosis (IDH wild-type, no 1p19q co-deletion, high CHI3L1 expression, and low NTRK2 expression) in the follow-up treatment of glioma [33]. The gene discussed is NTRK2; the disease is glioma.